STAT | Reporting from the frontiers of health and medicine Follow STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke. https://www.statnews.com/2026/07/23/new-data-on-eli-lilly-triple-g-drug-retatrutide-leave-open-questions-on-heart-benefit/ statnews.com
